On Demand Medical Testing

The characteristics of beta2 microglobulin (B2M) make it useful as a tumor marker for some blood cell cancers, for detecting kidney damage, and for distinguishing between glomerular and tubular disorders of the kidney. B2M is not diagnostic for a specific disease.

CA-125 is primarily used to monitor therapy during treatment for ovarian cancer. CA-125 is also used to detect whether cancer has come back after treatment is complete. Series of CA-125 tests that show rising or falling concentrations are often more useful than a single result. This test is sometimes used to test and monitor high-risk women who have a family history of ovarian cancer but who do not yet have the disease.

TUMOR MARKER

To monitor the response to treatment of invasive breast cancer and to watch for recurrence of the disease

CEA is used mainly to monitor the treatment of cancer patients, especially those with colon cancer. Following surgery, CEA values are helpful in monitoring the response to therapy and in determining whether the disease has recurred. CEA is also used as a marker for other forms of cancer, including cancers of the rectum, lung, breast, liver, pancreas, stomach, and ovary. Not all cancers produce CEA, and a positive CEA test is not always due to cancer.

A Complete Blood Count or CBCis a great test to take to give you a snapshotyour health. This test gives important information about the kind and the number of cells in your blood. Physicians use this information to evaluate symptoms, help diagnose conditions and treat certain illnesses (like infections).

Your adrenal glands are two small pieces of tissue that sit atop each kidney. They  produce and release certain regulatory hormones and chemical messengers - one of which is Dehydroepiandrosterone Sulfate or DHEA-S for short. It’s a natural steroid hormone produced from cholesterol and it purpose is to serve as a precursor to male and female sex hormones. This hormone is also associated with immune and stress response.

NSE is useful in monitoring disease progression and therapy in patients with small cell lung cancer and neuroendocrine tumors such as neuroblastoma, medullary thyroid carcinoma, and pheochromocytoma, and other malignancies such as pancreatic islet cell carcinoma